These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 17327379)
1. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. Eugster EA; Clarke W; Kletter GB; Lee PA; Neely EK; Reiter EO; Saenger P; Shulman D; Silverman L; Flood L; Gray W; Tierney D J Clin Endocrinol Metab; 2007 May; 92(5):1697-704. PubMed ID: 17327379 [TBL] [Abstract][Full Text] [Related]
2. The histrelin implant: a novel treatment for central precocious puberty. Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198 [TBL] [Abstract][Full Text] [Related]
4. Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant. Hirsch HJ; Lahlou N; Gillis D; Strich D; Rosenberg-Hagen B; Chertin B; Farkas A; Hartman H; Spitz IM J Clin Endocrinol Metab; 2010 Jun; 95(6):2841-4. PubMed ID: 20339028 [TBL] [Abstract][Full Text] [Related]
5. Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial. Silverman LA; Neely EK; Kletter GB; Lewis K; Chitra S; Terleckyj O; Eugster EA J Clin Endocrinol Metab; 2015 Jun; 100(6):2354-63. PubMed ID: 25803268 [TBL] [Abstract][Full Text] [Related]
6. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060 [TBL] [Abstract][Full Text] [Related]
7. Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty. Lewis KA; Eugster EA J Pediatr; 2013 Mar; 162(3):562-5. PubMed ID: 23040793 [TBL] [Abstract][Full Text] [Related]
8. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules. Roger M; Chaussain JL; Berlier P; Bost M; Canlorbe P; Colle M; Francois R; Garandeau P; Lahlou N; Morel Y J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759 [TBL] [Abstract][Full Text] [Related]
9. Time to menarche and final height after histrelin implant treatment for central precocious puberty. Gillis D; Karavani G; Hirsch HJ; Strich D J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026 [TBL] [Abstract][Full Text] [Related]
10. A single histrelin implant is effective for 2 years for treatment of central precocious puberty. Lewis KA; Goldyn AK; West KW; Eugster EA J Pediatr; 2013 Oct; 163(4):1214-6. PubMed ID: 23809043 [TBL] [Abstract][Full Text] [Related]
11. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629 [TBL] [Abstract][Full Text] [Related]
12. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test. Garibaldi LR; Aceto T; Weber C; Pang S J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study. Luo X; Zhang C; Yang Y; Xu X; Cheng X; Wei H; Wang L; Huang F; Shi X; Cabri P Adv Ther; 2023 Oct; 40(10):4574-4588. PubMed ID: 37584898 [TBL] [Abstract][Full Text] [Related]
14. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Carel JC; Blumberg J; Seymour C; Adamsbaum C; Lahlou N; Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000 [TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty. Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834 [TBL] [Abstract][Full Text] [Related]
16. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty. Kappy M; Stuart T; Perelman A; Clemons R J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570 [TBL] [Abstract][Full Text] [Related]
17. Effects of leuprolide in the treatment of central precocious puberty. Lee PA; Page JG J Pediatr; 1989 Feb; 114(2):321-4. PubMed ID: 2492599 [TBL] [Abstract][Full Text] [Related]
18. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone. Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399 [TBL] [Abstract][Full Text] [Related]
20. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment? Kunz GJ; Sherman TI; Klein KO J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1189-98. PubMed ID: 18183790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]